ITGA3 (Integrin Subunit Alpha 3)

Neutralization of CAFs-derived LAM332 impaired tumor cell proliferation and invasion, disrupted CTC cluster formation, increased apoptosis, reduced hepatic and pulmonary metastasis, and prolonged survival in mouse models. These findings uncover a CAFs-LAM332-ITGA3 axis that orchestrates CTCs formation and survival, and highlight this stromal-tumor interaction as a promising therapeutic target to mitigate metastatic progression in PDAC.

Collectively, 2-DAIL exerts its anti-CRC effects, at least partially, by binding to and inhibiting the function of ITGA3, thereby blocking the activation of the PI3K/AKT signaling pathway, which leads to CRC cell growth inhibition. Our study provides a promising drug candidate for the treatment of CRC and suggests the potential of 2-DAIL in treating other diseases linked to ITGA3 dysfunction.

Drug sensitivity prediction and molecular docking indicated that the monocarboxylate transporter 1 (MCT1) inhibitor AZD-3965 may have therapeutic potential in this context. In general, our findings suggest that migrasome-related genes may contribute to prognostic stratification of pancreatic cancer and point to mechanisms of stroma-immune crosstalk, thereby offering exploratory avenues for personalized treatment.

In keratinocytes, BMRGs such as integrins (ITGB1, ITGA3, ITGA6), laminins (LAMA3, LAMC1), CD44, and FN1 were upregulated in cSCC compared to AK or BD (adjusted p < 0.05); in fibroblasts, BMRGs including ITGB1, ITGAV, LUM, BGN, SDC1, and FN1 were upregulated in cSCC (adjusted p < 0.05), suggesting their collective role in BM breaching and invasion, as well as a higher risk of BD. This study provides novel biological insights into the differentiation of progression pathways from AK or BD to cSCC, as well as potential targets for therapeutic intervention.

Notably, suppression of CACNA1C induced transdifferentiation from stable/late-state cells to normal epithelium-like cells. This study provides novel insights into the EMT mechanism in ESCC, proposes an intervention strategy, and emphasizes the promising clinical application of pathological images in EMT assessment.

In HNSC, the high expression of ITGA3/5/6 serves as a biomarker for poor prognosis. Our research results indicate that ITGA family genes can serve as valuable prognostic biomarkers and therapeutic targets for tumors.

This validated ARG-based prognostic model effectively predicts survival outcomes and revealed strong associations between anoikis resistance, immune landscape alterations, and immunotherapy response, offering a framework for risk stratification and precision immunotherapy in LUSC clinical management.

NNK is associated with a malignant transcriptional program characterized by epithelial remodeling, stromal interaction, and immune suppression. These molecular features can be captured non-invasively through CT-based radiomics. The NNK-related ITGA3-associated radiomics (NIR) score provides a practical tool for preoperative risk stratification in PC and offers a bridge linking environmental carcinogen exposure with tumor imaging phenotypes.

A 2E7-MMAE (monomethyl auristatin E) ADC exhibited potent, dose-dependent antitumor activity in bladder cancer xenograft models, leading to tumor regression and prolonging survival. This study establishes a generalizable framework for function-first ADC discovery and nominates ITGA3B1 as a promising therapeutic target in bladder cancer.

Our findings indicate that epithelial cells undergo profound changes during lung cancer brain metastasis. ARGs, particularly CD44, play a critical role in this process and have prognostic significance for lung cancer brain metastasis.

Baseline EMT/adhesion signatures and stress-response pathways nominate CD44 and ITGA3/α3β1 as candidate biomarkers of resistance. These findings delineate molecular programs of β-emitter radioresistance and identify candidate pathways for future targeting.